Molecular markers like isocitrate dehydrogenase (IDH) mutations and O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status have gained substantial attention for their role in tumor classification, prognosis, and treatment planning. Here, IDH1 is linked to neoplasm.